Role of nitric oxide in sleep regulation: effects of -NAME, an inhibitor of nitric oxide synthase, on sleep in rats

The effect of N^G-nitro--arginine methyl ester (-NAME), a competitive inhibitor of enzyme nitric oxide synthase (NOS), on spontaneous sleep during the light period, was studied in adult rats implanted for chronic sleep recordings. -NAME was injected by subcutaneous (s.c.) or intracerebroventricular (i.c.v.) routes or was infused directly into the dorsal raphe nuclei (DRN). Subcutaneous (1.25–5.0 mg/kg) or i.c.v. (0.25–1.0 mg) administration of -NAME increased waking (W) and reduced slow wave sleep (SWS) and rapid-eye-movement sleep (REMS) during the first 3 h of recording. On the other hand, direct application of -NAME into the DRN (50.0–150.0 μg) induced an increment of W and a reduction of SWS without suppressing REMS. Values of W and SWS were significantly different compared with those of controls during the 6-h recording period. The effects of -NAME observed after s.c. or i.c.v. administration confirm previous studies in rabbits and rats, in which the NOS inhibitor reduced sleep and increased W in a dose-dependent manner. It is possible that REMS suppression after -NAME could be related to a reduction of acetylcholine release in areas critical for REMS promotion. A decrease in γ-aminobutyric acid (GABA) release after nitric oxide synthesis inhibition could play a role in the reduction of SWS.     

一氧化氮及一氧化氮合酶抑制剂在大鼠局灶性脑缺血时作用研究

目的：观察一氧化氮及一氧化氮合酶抑制剂在大鼠局灶性脑缺血时的作用方法;民凝大鼠大脑中动脉制成脑缺血模型,选择脑缺血３０ｍｉｎ,６０ｍｉｎ,１２０ｍｉｎ,１８０ｍｉｎ为研究时点,观察各时点用选择性,非选择性一氧化氮合酶抑制剂亚硝酸盐含量测定,缺血脑组织坏死体积测定及损伤海马ＣＡ１电镜观察。     

Antagonism of the nitric oxide synthase inhibitor, L-NAME, of the effects of phencyclidine on latent inhibition in taste aversion conditioning

Latent inhibition (LI) is a behavioural procedure used to evaluate the potential propsychotic and antipsychotic properties of psychoactive drugs. In the present study, a conditioned taste aversion (CTA) procedure was used to investigate the effects of the nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), and the psychotomimetic drugs, phencyclidine (PCP) and d-amphetamine (d-AMP) on LI. PCP (2 mg/kg) and d-AMP (0.5 mg/kg) were both found to enhance LI in this procedure. The effect of d-AMP on LI was less pronounced and this drug also caused a weak disruption of taste aversion conditioning. Pretreatment with L-NAME (10 mg/kg) blocked the LI enhancing effect of PCP on LI but not that of d-AMP. L-NAME by itself caused an attenuation of LI. L-NAME has been shown to block also other behavioural and biochemical effects of PCP in previous studies and these results and the present findings suggest that at least some of the effects PCP are dependent on NO and possibly also that some NOS inhibitors may exert antipsychotic properties.     

The nitric oxide synthase inhibitor L-NAME suppresses androgen-induced male-like pseudocopulatory behavior in whiptail lizards

The synthesis of nitric oxide by the enzyme nitric oxide synthase (NOS) is involved in the androgen-dependent gating of male-typical copulatory behavior, both centrally, particularly in the preoptic area, and peripherally, notably through its role in penile erection. In the all-female whiptail lizard species Cnemidophorus uniparens, individuals display copulatory behaviors indistinguishable from males of similar species if gonadectomized and treated with testosterone. In this experiment, androgenized individuals were treated with a NOS inhibitor, which eliminated male-like behavior in half the individuals, suggesting that the central role of nitric oxide synthesis is conserved in this species. The deficit was principally in mounting, suggesting that sexual motivational systems were affected, rather than consummatory mechanisms.     

Sleep and nitric: oxide: effects of 7-nitro indazole, inhibitor of brain nitric oxide synthase

We examined the effect of 7-nitro indazole (7-NI, 2.5–50 mg/kg, i.p.), an inhibitor of central nitric oxide (NO) synthesis, on general behaviour and sleep. The results show that 7-NI induces ptosis, a loss of the righting reflex and decrease of the EEG amplitudes. Furthermore, a duration of slow wave sleep (SWS) and REM sleep decreased, while the latencies of SWS and REM sleep increased. The effects of 7-NI on general behaviour and sleep were partially antagonized by intraventricular administration of the NO precursor,l-arginine (600 μg). These findings indicate that 7-NI induces a state of prominent central depression associated with motor deficit and decrease in sleep stages and wakefulness. It further suggests that NO exerts a significant excitatory effect on the neuronal structure involved in the regulation of locomotion and vigilance.     

The nitric oxide synthase inhibitor. L-NAME, blocks certain phencyclidine-induced but not amphetamine-induced effects on behaviour and brain biochemistry in the rat

1. 1. The present experiments examined the effects of the nitric oxide synthase (NOS) inhibitor, N^G-nitro-L-arginine methyl ester (L-NAME), on some behavioural and biochemical effects of phencyclidine (PCP) and d-amphetamine (AMPH) in rats. Observation of behaviour was performed using a subjective scoring system.

2. 2. PCP (4 mg/kg) increased locomotor activity, rearing, sniffing, grooming and stereotyped behaviour, and decreased stillness. PCP also increased forepaw myoclonus, forepaw treading, head weaving, licking and chewing behaviour. Most of these behaviours were significantly suppressed by pretreatment with L-NAME (10 mg/kg).

3. 3. AMPH (1 mg/kg) exerted different effects on behaviour. It increased locomotor activity, rearing, sniffing, and stereotyped behaviour, and decreased stillness and grooming, but failed to affect the other behavioural items observed. Pretreatment with L-NAME did not counteract these effects.

4. 4. Ex vivo biochemical analysis indicated that PCP increased the tissue concentration of the dopamine (DA) metabolites, dihydroxyphenyl acetic acid (DOPAC) and homovanillic acid (HVA), in the ventral striatum (i.e., the nucleus accumbens and olfactory tubercles) and frontal cortex but not in the dorsal striatum. DA was not significantly affected in any of these regions. Furthermore, PCP increased the tissue concentration of the serotonin (5-HT) metabolite, 5-hydroxyindole acetic acid (5-HIAA), in a similar manner, while 5-HT was not affected. These biochemical effects were significantly counteracted by pretreatment with L-NAME.

5. 5. AMPH decreased tissue DOPAC concentration in the dorsal striatum, an effect which was not sensitive to pretreatment with L-NAME. However, the combined treatment with L-NAME and AMPH increased tissue DA concentration in all three regions investigated.

6. 6. The neurochemical and behavioural effects of PCP and AMPH were further investigated in an experimental model which allowed measurement of prepulse inhibition (PPI) of acoustic startle in parallel with in vivo microdialysis sampling of extracellular DA concentration in the brain of awake, freely moving animals.

7. 7. Both PCP (2 mg/kg) and AMPH (2 mg/kg) caused a significant decrease in PPI of similar magnitude and duration. These behavioural effects were accompanied by a significant increase in extracellular DA concentration in the nucleus accumbens (PCP: 213 ± 21% of basal concentration; AMPH: 563±117%).

8. 8. The decrease in PPI caused by PCP was blocked by pretreatment with L-NAME, but the change in DA concentration was not. Neither of these measures were significantly affected by L-NAME in AMPH-treated rats.

9. 9. In conclusion, this study shows that several behavioural and biochemical effects of PCP are prevented by pretreatment with the NOS inhibitor, L-NAME, while the effects of AMPH are less sensitive to this pretreatment. These observations emphasise the involvement of nitric oxide in the pharmacological effects of PCP.

     

Microinjection of the nitric oxide synthase inhibitor L-NAME into the lateral basal forebrain alters the sleep/wake cycle of the rat

The effects of N(G)-nitro-L-arginine methyl ester (L-NAME) (0.19-0.74 micromol), a competitive inhibitor of the enzyme nitric oxide synthase (NOS); L-arginine (48.0-191.0 nmol), a nitric oxide (NO) precursor; and molsidomine (0.06-0.24 nmol), an NO donor, on spontaneous sleep were studied in adult rats implanted for chronic sleep recordings. Direct bilateral application of L-NAME into the nucleus of the horizontal limb of the diagonal band of Broca (HDB) increased waking (W) and reduced slow wave sleep (SWS). On the other hand, intra-HDB injection of L-arginine or molsidomine induced slight but inconsistent changes of sleep variables that did not attain significance. Pretreatment with L-arginine (191.0 nmol) or molsidomine (0.24 nmol) prevented the increase of W and the reduction of SWS induced by L-NAME (0.37 micromol), thus indicating that a decrease in the availability of NO may be involved in the effects of L-NAME on sleep variables. An increase in the release of acetylcholine (ACh) and/or a reduction in the output of gamma-aminobutyric acid (GABA) and adenosine could tentatively explain the effects of L-NAME on SWS and W.     

一氧化氮合酶抑制剂对缺血性海马迟发性神经元死亡的保护作用

目的：研究一氧化氮在缺血性海马迟发性神经元死亡中的作用,观察非选择性一氧化氮合酶抑制剂Ｎ＾Ｇ－ｎｉｔｒｏ－Ｌ－ａｒｇｉｎｉｎｅ对缺血性海马ＤＮＤ的影响。方法：实验分为假手术组,生理盐水治疗组,Ｌ－ＮＮＡ治疗组。采用大鼠４血管关闭方法制作了全脑缺血再灌流模型,以假手术组为对照,检测了脑缺血１０ｍｉｎ再灌流７２ｈ海马区ＮＯＳ活性的变化并观察计量了海马ＣＡ１区组织病理改变;     

L—NAME加强麻醉大鼠低血压诱发的催产素释放作用

取戊巴比妥麻醉大鼠向侧脑室内分别注射一氧化氮合酶的底物Ｌ－精氨酸和ＮＯ合酶抑制剂Ｎ＾Ｇ－硝基－Ｌ－精氨酸甲酯,用放射免疫法测定血浆中催产素水平。结果：侧脑室内注射Ｌ－精氨酸（１００ｇ／Ｌ,１０μＬ,ｎ＝８）和Ｌ－ＮＡＭＥ（５４．０ｔ／Ｌ,５μＬ,ｎ＝１２）,对Ｏ物基础分泌无明显的影响;侧脑室内注射５μＬ Ｌ－ＮＡＭＥ（剂量（１：２７,ｇ／Ｌ,ｎ＝９;剂量２：５４。０ｇ／Ｌｎ＝９）可进一步增强静脉输     

L-NAME加强麻醉大鼠低血压诱发的催产素释放作用

取戊巴比妥麻醉大鼠向侧脑室内分别注射一氧化氮(NO)合酶的底物L-精氨酸和NO合酶抑制剂NG-硝基-L-精氨酸甲酯(L-NAME),用放射免疫法测定血浆中催产素(OT)水平.结果:侧脑室内注射L-精氨酸(100 g/L,10 霯,n=8)和L-NAME(54.0 g/L,5 霯,n=12),对OT的基础分泌无明显影响;侧脑室内注射5 霯 L-NAME(剂量1:27.0 g/L,n=9;剂量2:54.0 g/L,n=8),可进一步增强静脉输注硝普钠引起低血压所诱导的OT分泌升高反应.结果表明L-NAME能加强低血压诱发的OT反射性释放作用,提示NO可能是OT反射性释放的抑制因子.     

Effect of central and peripheral administration of a nitric oxide synthase inhibitor on morphine hyperthermia in rats

The effect of central and peripheral administration of a nitric oxide synthase inhibitor, N-nitro-L-arginine methyl ester (L-NAME), on morphine hyperthermia was studied in male Sprague-Dawley rats. The first series of experiments examined the effect of subcutaneous (s.c.) administration of L-NAME on the hyperthermia induced by morphine given s.c. in doses of 4 and 15 mg/kg. L-NAME, at a s.c. dose of 50 mg/kg, per se, had no influence on body temperature (T(b)). Coadministration of L-NAME (50 mg/kg, s.c.) with the higher dose of morphine (15 mg/kg, s.c.) caused a significant suppression of morphine hyperthermia during the first 30 min and then produced hypothermia. In contrast, s.c. injection of L-NAME (50 mg/kg, s.c.) failed to alter the hyperthermic response induced by the lower dose of morphine (4 mg/kg). In the second series of experiments, we investigated the effect of intracerebroventricular (i.c.v.) administration of L-NAME on the hyperthermia induced by morphine given s.c. L-NAME, itself, given i.c.v. at a dose of 1 mg did not evoke any change in T(b). Intracerebroventricular administration of L-NAME (1 mg) blocked the hyperthermia induced by 15 mg/kg morphine during the first 30 min and induced a slight hypothermia but did not alter the hyperthermia induced by 4 mg/kg morphine. The results indicate that either central or peripheral NO synthesis is required for the production of hyperthermia induced by 15 mg/kg of morphine. However, NO synthesis does not seem to be involved in the hyperthermic process induced by 4 mg/kg of morphine.     

7-nitroindazole, nitric oxide synthase inhibitor, attenuates physical dependence on butorphanol in rat

Butorphanol is a synthetic opioid agonist/antagonist analgesic agent that mainly exerts its effects through kappa-opioid receptors. It has been demonstrated that kappa-opioid receptors preferentially mediate the development of physical dependence upon butorphanol and the associated withdrawal syndrome. However, it is not fully understood whether or not nNOS-containing neurons in the various brain regions play an important role in butorphanol withdrawal. Therefore, this study was conducted to determine whether the selective nNOS inhibitor, 7-NI, modifies the development of butorphanol withdrawal and changes of nNOS expressions in different brain regions in physically butorphanol-dependent rats. The first part of the study focused on withdrawal behaviors in male Sprague-Dawley rats. Physical dependence was induced by a 72-h i.c.v. infusion with butorphanol (26 nmol/mixrol/h) and withdrawal was subsequently precipitated by i.c.v. challenge with naloxone (48 nmol/5 microl/rat) 2 h after termination of the butorphanol infusion. The butorphanol/7-NI coadministration group showed a significant decrease in several signs of withdrawal such as teeth chattering, as compared with the butorphanol-treated group. In the second part of the study, immunohistochemical analysis was performed to determine the expression of nNOS in the various brain regions. In the butorphanol/7-NI coadministration group, the number of cells labeled for nNOS was significantly lower in the various brain regions (including the caudate putamen, nucleus accumbens, and hippocampus) than in the butorphanol group. Therefore, 7-NI decreased in butorphanol-induced physical dependence and nNOS expression. Taken together, these findings suggest that the nNOS system is involved in the development of butorphanol-induced physical dependence, and 7-NI has potential clinical application as a candidate for the treatment of opioid withdrawal syndrome.     

Antiepileptic effects of inhibitors of nitric oxide synthase examined in pentylenetetrazol-induced seizures in rats

The effects of intraperitoneal and methyl ester, specific inhibitors of nitric oxide (NO) synthase, were examined on the pentylenetetrazol (PTZ)-induced seizures in rats. The incidence and latency for the onset of myoclonic jerks, clonic seizures, and tonic generalized extension were observed as specific parameters among PTZ-induced seizures. Both drugs preferentially suppressed the tonic generalized extension and prolonged the latency for the onset of each parameter, suggesting NO has a significant effect on the PTZ-induced seizure.     

Long-term neuroprotection with 2-iminobiotin, an inhibitor of neuronal and inducible nitric oxide synthase, after cerebral hypoxia-ischemia in neonatal rats.

The short- and long-term neuroprotective effects of 2-iminobiotin, a selective inhibitor of neuronal and inducible nitric oxide synthase, were studied in 12-day-old rats following hypoxia-ischemia. Hypoxia-ischemia was induced by occlusion of the right carotid artery followed by 90 minutes of hypoxia (FiO2 0.08). Immediately on reoxygenation, 12 and 24 hours later the rats were treated with vehicle or 2-iminobiotin at a dose of 5.5, 10, 30, or 60 mg/kg per day. Histologic analysis of brain damage was performed at 6 weeks after hypoxia-ischemia. To assess early changes of cerebral tissue, levels of HSP70, nitrotyrosine, and cytochrome c were determined 24 hours after reoxygenation. Significant neuroprotection was obtained using a dose of 30 mg/kg per day of 2-iminobiotin. Levels of HSP70 were increased in the ipsilateral hemisphere in both groups (P<0.05), but the increase was significantly (P<0.05) less in the rats receiving the optimal dose of 2-iminobiotin (30 mg/kg per day). Hypoxia-ischemia did not lead to increased levels of nitrotyrosine, nor did 2-iminobiotin influence levels of nitrotyrosine. In contrast, hypoxia-ischemia induced an increase in cytochrome c level that was prevented by 2-iminobiotin. In conclusion, 2-iminobiotin administered after hypoxia-ischemia provides long-term neuroprotection. This neuroprotection is obtained by mechanisms other than a reduction of nitrotyrosine formation in proteins.     

局灶性鼠脑缺血时一氧化氮及一氧化氮合酶抑制剂的作用机制

目的研究一氧化氮在鼠脑局灶性脑缺血再灌注损伤中的作用。方法用线栓法建立大鼠大脑中动脉区缺血再灌注模型，分别用选择性和非选择性诱导型一氧化氮合酶抑制剂对鼠脑局灶性缺血再灌注过程中脑组织一氧化氮的变化规律及可能作用进行探讨。结果非选择性一氧化氮合酶抑制剂（Ｌ－ＮＡＭＥ）可加重局灶性脑缺血性损害，而选择性诱导型一氧化氮合酶抑制剂（ａｍｉｎｏｇｕａｎｉｄｉｎｅ，ＡＧ）具有明确的脑保护作用。结论不同类型的一氧化氮合酶所产生的一氧化氮在脑局灶性缺血性损害中具有不同的作用。     

Synergistic protective effects of antioxidant and nitric oxide synthase inhibitor in transient focal ischemia.

Both nitric oxide synthase (NOS) inhibitors and free radical scavengers have been shown to protect brain tissue in ischemia-reperfusion injury. Nitric oxide and superoxide anion act via distinct mechanisms and react together to form the highly deleterious peroxynitrite. Therefore the authors examined the effects and the interaction between the NOS inhibitor, NG nitro-L-arginine (LNA) and the antioxidant/superoxide scavenger, di-tert-butyl-hydroxybenzoic acid (DtBHB) in the rat submitted to 2 hours of middle cerebral artery occlusion. Posttreatment was initiated 4 hours after the onset of ischemia and infarct volume was measured at 48 hours. The dose-related effect of LNA resulted in a bell-shaped curve: 15, 56, 65, and 33% reduction of total infarct for 0.03, 0.1, 0.3, and 1 mg/kg (intravenously [IV]) respectively and 11% increase in infarct volume for 3 mg/kg (IV). Whereas DtBHB (20 mg/kg; intraperitoneally [IP]) was ineffective, the dose of 60 mg/kg produced 65% protection in infarct volume. The combination of a subthreshold dose of LNA (0.03 mg/kg; IV) and DtBHB (20 mg/kg; IP) resulted in significant reduction (49%) in infarct volume. These results show that LNA and DtBHB act synergistically to provide a consistent neuroprotection against ischemic injury when administered 4 hours after ischemia. This suggests that nitric oxide and free radicals are involved and interact in synergy in ischemia-reperfusion injury.     

Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase

This study assessed the role of de novo nitric oxide (NO) production in the pathogenesis of experimental allergic encephalomyelitis (EAE) by using aminoguanidine (AG), an inhibitor of nitric oxide synthase (NOS). which preferentially inhibits the cytokine- and endotoxin-inducible isoform of NOS versus the constitutive isoforms consisting of endothelial and neuronal NOS. The maximum clinical severity of EAE and the duration of illness were significantly reduced or totally inhibited by twice daily subcutaneous injection of 100 mg/kg body weight AG. Histochemical staining for NADPH diaphorase, which detects enzymatic activity of NOS, revealed positive reactivity in untreated EAE rats both in parenchymal blood vessel walls and in anterior horn cell neurons, while normal rats and rats with EAE treated with AG showed predominantly the neuronal positivity. Moreover, this NADPH staining pattern was further supported by the immunohistochemical findings that endothelial NOS (eNOS) expression was increased in blood vessels in the inflamed lesions of untreated EAE rats and that inducible NOS (iNOS) was detected in some infiltrating inflammatory cells, while treatment with AG could significantly reduce both iNOS and eNOS production. These results suggest that: (i) both iNOS and eNOS are upregulated in inflamed areas of the rat central nervous system in EAE; (ii) increased NO production plays a role in the development of clinical signs in EAE; and (iii) selective inhibitors of iNOS and/or eNOS may have therapeutic potential for the treatment of certain autoimmune diseases.     

NOS抑制剂对局灶性缺血再灌流大鼠脑神经细胞凋亡的影响研究

目的 研究一氧化氮合酶（ＮＯＳ）抑制剂在局灶性脑缺血再灌流过程中对神经细胞的作用机理,特别是ＮＯＳ抑制剂（ＮＮＬＡ）与细胞凋亡的关系。方法 利用末端标记法,测定ＮＮＬＡ干预后局灶性脑缺血鼠脑组织中神经细胞的凋亡情况。结果 大、小剂量的ＮＯＳ抑制剂分别具有增加或减少阳性凋亡细胞出现率的作用。结论 给予不同剂量的ＮＯＳ抑制剂与单纯缺血再灌流相比,对脑神经细胞的凋亡出现率有不同的影响。